Target
glycinamide ribonucleotide formyltransferase (GART)
1 abstract
Abstract
Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).Org: Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China, Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China, Guangzhou, China, Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen, China, Department of Thoracic Surgery, Cancer Center of Guangzhou Medical University, Guangzhou, China,